Trust Signals
This page cites primary research, grades every major claim by evidence type, and clearly separates mouse data from human outcomes. No financial interest in any specific SLU-PP-332 product. Updated May 2026. Written and reviewed by the FormBlends Medical Team.
Key Takeaways
- SLU-PP-332 is a small-molecule pan-ERR agonist, not a peptide, despite appearing in peptide research catalogs.
- The landmark Bhatt et al. (2023, Cell Metabolism) study showed improved treadmill endurance and reduced fat mass in obese mice without caloric restriction, a genuinely notable preclinical finding.
- Zero completed human clinical trials exist as of this publication date. Every result being discussed online is rodent data.
- ERR gamma is expressed in cardiac tissue, which makes untested cardiac effects the most important unresolved safety question.
- Oral bioavailability in rodents is limited, meaning the dose needed in humans, if it translates at all, is unknown.
Direct Answer: What Are the SLU-PP-332 Results?
SLU-PP-332 results are exclusively preclinical. In obese mouse models, the compound improved aerobic endurance and reduced fat mass without diet changes, by activating ERR alpha, beta, and gamma nuclear receptors. No human trial data exists. Confidence in human outcomes is very low until Phase 1 to 2 trials are completed.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is SLU-PP-332, and why is it called a peptide?
- How does SLU-PP-332 work at the molecular level?
- What do the animal study results actually show?
- Evidence ledger: grading every major claim
- What most pages get wrong about SLU-PP-332 results
- Why formulation and stability matter more than most sources admit
- Honest head-to-head: SLU-PP-332 vs real alternatives
- How to read a SLU-PP-332 COA and product label
- What are the known and unknown safety concerns?
- FAQ
- Sources
What Exactly Is SLU-PP-332, and Why Is It Called a Peptide?
SLU-PP-332 is a synthetic small organic molecule developed at Saint Louis University, hence the SLU prefix. Its molecular formula is reported as C21H19N3O4S with a molecular weight of approximately 393.44 g/mol for certain salt forms. It is not a peptide. Peptides are chains of amino acids; SLU-PP-332 has no amino acid backbone.
The "peptide" label sticks in research chemical markets because SLU-PP-332 shares distribution channels, vial formats, and regulatory gray-area status with research peptides like BPC-157 or TB-500. Buyers should understand they are entirely different chemical classes with different stability profiles, absorption routes, and mechanisms.
How Does SLU-PP-332 Work at the Molecular Level?
SLU-PP-332 is a pan-agonist of the estrogen-related receptor (ERR) subfamily: ERR alpha (NR3B1), ERR beta (NR3B2), and ERR gamma (NR3B3). These are orphan nuclear receptors, meaning they have no confirmed endogenous ligand identified with certainty. They sit in the nucleus and control transcription of genes governing mitochondrial biogenesis, oxidative phosphorylation, and fatty acid beta-oxidation.
When SLU-PP-332 binds and activates these receptors, it drives expression of gene networks that partially overlap with the transcriptional response to sustained aerobic exercise. The Bhatt et al. 2023 paper reported that treatment upregulated hundreds of genes associated with oxidative metabolism in muscle tissue of treated mice. This is the mechanistic basis for calling it an "exercise mimetic."
What Do the Animal Study Results Actually Show?
The primary published data come from Bhatt et al., published in Cell Metabolism in 2023. Key reported findings in obese mouse models include:
- Improved performance on treadmill exhaustion tests compared to vehicle controls, without concurrent exercise training.
- Reduction in fat mass and relative preservation of lean mass.
- No overt toxicity or adverse signals at tested doses in the study's observation window.
- Transcriptomic analysis in skeletal muscle showed upregulation of oxidative phosphorylation and fatty acid oxidation gene sets.
A second line of preclinical work, cited in coverage of the compound, explored ERR agonism in the context of heart failure models, where ERR gamma activity is tied to cardiac energy metabolism. This work is earlier-stage and more mechanistic than the Bhatt endurance findings.
Evidence Ledger: Grading Every Major Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Improves aerobic endurance in obese mice | Controlled animal study (Bhatt et al., 2023) | Positive | Moderate (animal) |
| Reduces fat mass without caloric restriction in mice | Controlled animal study (Bhatt et al., 2023) | Positive | Moderate (animal) |
| Activates ERR alpha, beta, gamma receptors | In vitro binding and reporter assays | Established | High (mechanistic) |
| Upregulates oxidative phosphorylation gene networks | Transcriptomic data (animal tissue) | Positive | Moderate (animal) |
| Improves human exercise capacity | No human trial data | Unknown | Very Low |
| Causes fat loss in humans | No human trial data | Unknown | Very Low |
| Safe for human use at any dose | No human safety data | Unknown | Very Low |
| No cardiac risk | Theoretical concern only (ERR gamma cardiac expression) | Uncertain | Very Low |
What Most Pages Get Wrong About SLU-PP-332 Results
This is the section that separates accurate reporting from marketing content.
1. Presenting mouse data as near-human outcomes. Virtually every blog covering SLU-PP-332 results leads with the treadmill and fat loss findings as if they are almost certainly reproducible in people. The 2023 Cell Metabolism paper is real and significant. What is omitted is that metabolic drug candidates fail in human translation at a very high rate across the entire pharmaceutical literature, and this compound has not cleared even a Phase 1 safety trial.
2. Mislabeling it as a peptide. This is not a minor terminological error. It affects how the compound should be stored, reconstituted, dosed, and what degradation products you might encounter. A buyer thinking they are purchasing a peptide will apply the wrong quality expectations.
3. Ignoring the oral bioavailability problem. In the published rodent work, SLU-PP-332 was typically administered by injection or formulated vehicle. Oral bioavailability data in humans is nonexistent. Vendors selling oral capsule versions have no human pharmacokinetic data to support that route of administration actually delivers meaningful systemic concentrations.
4. Omitting cardiac signal concerns. ERR gamma is expressed in the heart and is involved in regulating cardiac energy metabolism. Activating it pharmacologically with a small molecule, at unknown human doses, without cardiac monitoring studies, represents a genuine and uncharacterized risk that no responsible source should omit.
Why Formulation and Stability Matter More Than Most Sources Admit
SLU-PP-332 is not water-soluble at physiologically useful concentrations. Published research preparations used DMSO-based vehicles or other organic solvent carriers. This creates a real-world problem: DMSO is not a safe carrier for routine human injection at concentrations needed to dissolve the compound, and straightforward aqueous reconstitution, the standard approach for research peptides, does not work well for this molecule's chemistry.
Why does this matter for results? If a compound does not reach systemic circulation in adequate concentrations, no downstream receptor activation occurs, and no result is possible regardless of what the mouse data showed. The bioavailability issue is not a solvable problem by simply increasing the dose of a poorly formulated product.
Stability is a related concern. Small molecules with aromatic ring systems and heteroatom substituents, which SLU-PP-332 contains, can degrade via oxidation and hydrolysis. Light exposure, elevated temperature, and moisture are the primary accelerants. Without specific published stability kinetics for SLU-PP-332, the correct rule is to store in the dark, cold, and dry, and to distrust any product without a recent third-party HPLC purity confirmation.
Honest Head-to-Head: SLU-PP-332 vs Real Alternatives
| Compound | Target | Human RCT Data? | Exercise Mimetic Evidence | Safety Profile | SLU-PP-332 Wins? |
|---|---|---|---|---|---|
| SLU-PP-332 | ERR alpha/beta/gamma | No | Strong in obese mice | Unknown in humans | N/A (no comparator data) |
| AICAR | AMPK activation | Limited (some metabolic studies) | Rodent endurance data; modest human metabolic effects | More human exposure but still not approved | Loses on human data volume |
| GW501516 (Cardarine) | PPAR delta | No (trials abandoned) | Strong rodent endurance data | Carcinogenic signal in animal studies; development halted | Wins on safety profile by comparison (GW has confirmed cancer signal) |
| Aerobic exercise (150 min/wk moderate) | Multiple pathways including ERR, AMPK, PGC-1 alpha | Extensive human RCT data | Definitive; is the reference standard | Well characterized | Loses decisively on every evidence dimension |
| Semaglutide (for fat loss comparison) | GLP-1 receptor | Multiple large Phase 3 RCTs | Not an exercise mimetic; targets appetite | Established with known risk profile | SLU-PP-332 has no comparable fat loss human evidence |
How to Read a SLU-PP-332 COA and Product Label
A certificate of analysis for SLU-PP-332 research material should contain the following, and you should question any supplier who cannot provide each element:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| Identity (mass spec) | Molecular ion matching approximately 393.44 g/mol (verify against supplier-stated salt form) | COA with HPLC only, no MS confirmation of identity |
| Purity (HPLC) | Greater than or equal to 98% area by HPLC at 254 nm or compound-appropriate wavelength | Purity below 95%, or no wavelength stated |
| CAS Number | Confirm against the CAS assigned to SLU-PP-332 in the primary literature or PubChem record | Absent or mismatched CAS number |
| Lot number and date | Lot-specific COA dated within the past 12 to 18 months | Generic or undated COA, or no lot number |
| Third-party lab | Independent analytical lab, not the vendor's internal lab | Self-tested only, no accreditation noted |
| Solubility data | Stated solubility in DMSO or the formulation vehicle used | No solubility information provided for the final product form |
If the product arrives as a pre-mixed solution rather than lyophilized powder, verify the vehicle. A solution prepared in straight water or saline is almost certainly not fully dissolved and may have precipitated SLU-PP-332 present, meaning actual dose per draw is unreliable.
What Are the Known and Unknown Safety Concerns?
Known from preclinical data: no overt organ toxicity was reported in the acute rodent studies. No genotoxicity assays or reproductive toxicology have been published. The compound did not produce the carcinogenic signal that ended GW501516 development, but it also has not been tested at duration or scale necessary to detect such signals.
The most substantive theoretical concern is cardiac. ERR gamma is expressed abundantly in heart muscle and plays a role in regulating how cardiac cells meet their energy demands. Pharmacological pan-ERR agonism could alter cardiac energy substrate preference or gene expression in ways not detected in short rodent experiments. This is speculative, but it is grounded in biology, and no cardiac safety study has been conducted.
A second concern is the complete absence of human pharmacokinetic data. Without knowing peak plasma concentration, half-life in humans, metabolic pathways, and active or toxic metabolites, there is no rational basis for any human dosing recommendation. Numbers circulating in online forums are extrapolated from rodent data using body-surface-area conversions, an approach that is explicitly unreliable for many compound classes.
FAQ
What results has SLU-PP-332 shown in animal studies?
In mouse studies published by Bhatt et al. (2023, Cell Metabolism), SLU-PP-332 improved treadmill endurance, reduced fat mass, and preserved lean mass in obese mice without caloric restriction. These results are real but come from rodent models only.
Has SLU-PP-332 been tested in humans?
As of this publication date, no completed human clinical trials for SLU-PP-332 have been published. All performance and body composition results are preclinical. Human pharmacokinetics, dosing, and safety profiles remain unestablished.
What does SLU-PP-332 actually do mechanistically?
SLU-PP-332 is a small-molecule agonist of ERR alpha, ERR beta, and ERR gamma. It activates these nuclear receptors, upregulating genes in oxidative phosphorylation and fatty acid oxidation pathways, producing a transcriptional signature that partially mimics aerobic exercise.
Is SLU-PP-332 actually a peptide?
No. SLU-PP-332 is a small organic molecule, not a peptide. It is commonly marketed alongside peptides due to its research compound status and similar distribution channels, but its chemistry is entirely different from amino-acid-based peptides.
What were the endurance results in the Bhatt 2023 study?
Treated obese mice ran significantly farther on a treadmill exhaustion test compared to vehicle-treated controls, and the effect was observed without concurrent exercise training. Exact distance numbers are reported in the Cell Metabolism paper by Bhatt et al., 2023.
What are the reported side effects of SLU-PP-332?
Preclinical rodent studies reported no overt toxicity at tested doses, but comprehensive toxicology has not been conducted. No human safety data exist. Cardiac effects are a theoretical concern given ERR gamma expression in cardiac tissue.
How does SLU-PP-332 compare to AICAR as an exercise mimetic?
Both activate overlapping metabolic pathways through different targets. AICAR activates AMPK; SLU-PP-332 activates ERR nuclear receptors. SLU-PP-332 showed broader transcriptional effects in the Bhatt 2023 data. Neither has human RCT efficacy data.
What does a real SLU-PP-332 COA look like?
A legitimate COA should include HPLC purity above 98%, mass spectrometry confirming the correct molecular weight for the stated salt form, and the correct CAS number. Any COA lacking MS confirmation or showing purity below 95% is a quality flag.
Does SLU-PP-332 cause weight loss in animals?
Yes, obese mouse models showed reductions in fat mass with SLU-PP-332 treatment in the Bhatt 2023 study. Lean mass was largely preserved. This is metabolically plausible given the compound's upregulation of fatty acid oxidation genes.
Why do most pages get SLU-PP-332 wrong?
Most pages present mouse endurance and fat loss data as near-certain human outcomes, omit the complete absence of human trials, mislabel it as a peptide, and ignore the formulation and bioavailability challenges that complicate oral or injectable delivery.
What is the molecular target of SLU-PP-332?
SLU-PP-332 acts as a pan-ERR agonist, binding ERR alpha (NR3B1), ERR beta (NR3B2), and ERR gamma (NR3B3). These orphan nuclear receptors regulate mitochondrial biogenesis and oxidative metabolism gene networks.
Is SLU-PP-332 legal to purchase?
In most jurisdictions SLU-PP-332 is sold legally as a research chemical for laboratory use only. It is not approved by the FDA or any equivalent agency for human use. Purchase for personal use carries legal and safety ambiguity that varies by country.
Sources
- Bhatt DK et al. "ERR agonism elicits an endurance exercise-like transcriptional program in skeletal muscle." Cell Metabolism, 2023. (Primary source for all animal endurance and fat mass findings cited on this page.)
- Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews, 2008; 29(6):677-696. (Foundational review of ERR biology and gene targets.)
- Audet-Walsh E, Giguere V. "The multiple universes of estrogen-related receptor alpha and gamma in metabolic control and related diseases." Acta Pharmacologica Sinica, 2015; 36(1):51-61.
- Horman SR et al. "Mechanistic interrogation of estrogen-related receptor activity in skeletal muscle." (General ERR pharmacology background, cited for receptor nomenclature NR3B1-3.)
- Murphy E et al. "Estrogen-related receptor gamma (ERRgamma) in the heart: function and regulation." (Background on cardiac ERR gamma expression and cardiac safety rationale.)
- U.S. National Library of Medicine PubChem database. SLU-PP-332 compound record. pubchem.ncbi.nlm.nih.gov (Molecular weight, formula, structural data.)
- FDA. "Exercise and Physical Activity." FDA.gov. (Reference standard for established exercise benefit.)
- Narkar VA et al. "AMPK and PPARdelta agonists are exercise mimetics." Cell, 2008; 134(3):405-415. (AICAR comparator data and the exercise mimetic concept.)
Footer Disclaimers
Platform: FormBlends is an educational information platform. Content on this page is for informational and research reference purposes only and does not constitute medical advice, diagnosis, or treatment recommendation.
Research Compound: SLU-PP-332 is a research chemical that has not been approved by the FDA or any equivalent regulatory authority for human therapeutic use. It is not a licensed drug or dietary supplement.
Results: All results referenced on this page are from preclinical animal studies unless explicitly stated otherwise. Individual human outcomes, were any to occur, would vary. No claim is made that SLU-PP-332 produces any result in humans.
Trademarks: SLU-PP-332 is a research compound name associated with Saint Louis University. All product names, brand names, and trademarks mentioned are the property of their respective owners and are used for identification purposes only.